SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing extreme volatility driven by a conflicting narrative between a market-moving announcement from Donald Trump regarding a potential ceasefire with Iran and immediate, emphatic denials from Iranian state media. The community is sharply divided, with bulls cheering the prospect of de-escalation and potential liquidity injections, while bears and skeptics are accusing the administration of cynical market manipulation to stave off a broader sell-off.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility driven by a combination of broader macroeconomic headwinds, including rising oil prices and interest rate uncertainty, and a persistent, high-profile short report from Muddy Waters that has sparked intense debate over the company's accounting practices and growth sustainability. While some investors are bracing for further downside and expressing skepticism, a vocal segment of the community remains focused on CEO Anthony Noto's recent insider buying as a signal of long-term conviction and potential undervaluation.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is at the center of significant investor enthusiasm following the removal of its CEO and key management team, signaling a major leadership overhaul that stakeholders hope will unlock shareholder value. The community is actively debating the potential for an imminent buyout or strategic sale, closely monitoring the influence of major shareholder Kevin Tang as they look for progress on the company's pipeline and patent negotiations.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing extreme volatility as market participants react to conflicting signals regarding the ongoing conflict with Iran, including unsubstantiated reports of imminent ceasefire talks and threats of further infrastructure strikes. Community discourse remains deeply divided between those betting on a prolonged supply crunch and those anticipating rapid de-escalation, all while traders adjust their positions to navigate the unpredictable impact of geopolitical headlines on crude prices.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing intense volatility as investors react to conflicting headlines regarding potential ceasefire talks with Iran, with community sentiment split between skepticism over potential market manipulation and hopes for a de-escalation of regional tensions. Traders are actively debating the authenticity of administration statements versus official denials from Tehran, leading to sharp price swings as the market gauges the broader impact of geopolitical uncertainty on tech and energy stocks.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is trending due to a significant volume surge and investor interest driven by supply chain disruptions in the Middle East following infrastructure damage to major LNG facilities. The community is actively debating the stock's potential for further upward movement amidst geopolitical tensions, while keeping a close watch on technical support levels and the risk of volatility common in low-float energy plays.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors react to a bipartisan Senate bill aimed at banning sports betting contracts on prediction markets like Polymarket and Kalshi. While community sentiment remains split on the stock's long-term volatility and management's handling of aggressive growth, many traders are closely watching the potential for the company to leverage its established sportsbook infrastructure against newer prediction market competitors.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as investors react to high-stakes political maneuvering in the Middle East, with community discussion sharply divided over the potential for a market-moving deal versus concerns about escalating geopolitical risks. Traders remain hyper-focused on the stock's sensitivity to headline-driven volatility, fueling intense debate regarding its role as both a platform for discourse and a barometer for the current administration's market influence.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is trending as traders closely monitor geopolitical tensions in the Middle East and their impact on energy prices and broader market sentiment. The community is actively debating the reliability of ceasefire headlines, with many investors adjusting their portfolios to hedge against volatility while navigating conflicting signals regarding Fed rate policy.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil (SCO) is attracting heavy volume as traders pivot to hedge against or bet against the recent volatility in crude oil prices driven by geopolitical tensions in the Strait of Hormuz. While some investors are scaling into the position expecting a eventual normalization in oil supply and a price correction, the community is actively debating the impact of the ETF's daily decay and the potential for rapid price swings as news regarding energy infrastructure and global strategic reserve releases continues to emerge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>SENTI-202, the immune cell therapy cancer treatment, received a Regenerative Medicine Advanced Therapy (RMAT) designation that would make it eligible for quicker reviews.</li><li>This is the second FDA designation for the treatment this year.&nbsp;</li><li>On Stocktwits, retail sentiment for the stock rose to ‘extremely bullish’ territory while message volume jumped to ‘extremely high’ levels at the time of writing. &nbsp;</li></ul>Shares of Senti Biosciences, Inc. (SNTI) surged over 20% on Tuesday’s premarket trading after the company announced positive news around its cancer treatment.&nbsp;The clinical-stage biotech company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.sentibio.com/news-releases/news-release-details/senti-bio-announces-updated-senti-202-clinical-data-ongoing">announced</a> in a press release that the U.S. Food and Drug Administration (FDA) gave SENTI-202, an immune cell therapy cancer treatment, a Regenerative Medicine Advanced Therapy (RMAT) designation.&nbsp;<h2 class="st-heading-2">What Does This Mean?</h2>The RMAT designation from the FDA for the company’s cancer treatment indicates an expedited development and review, providing benefits similar to the FDA’s Breakthrough Therapy and the Fast Track programs such as higher interactions with the Agency through the development process as well as eligibility for quicker and even priority reviews.“This significant FDA designation validates both the tremendous need for better treatments for R/R AML and the promise of SENTI-202 to transform the therapeutic landscape for this notoriously aggressive cancer,” said Timothy Lu, Co-Founder and CEO of Senti Biosciences, in the press release. “We are incredibly pleased with the exciting clinical progress we recently shared at the ASH conference on SENTI-202.”Data from its ongoing trial showed a 50% overall response rate and 42% complete remission at the recommended Phase 2 dose, the company revealed. Earlier this year, the U.S. FDA granted the treatment Orphan Drug Designation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/SNTI">SNTI</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1284/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_7_13_22_PM_png_c037e194c0.webp" alt="On Stocktwits, retail sentiment around&nbsp;SNTI jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels." width="1284" height="149"></figure>One user on the platform predicted that STNI’s share price could go up to $5. The stock was trading around $2.85 at the time of writing.&nbsp;<stembedurl>https://stocktwits.com/Stratsys/message/638587949</stembedurl>Shares of SNTI have fallen over 37% year to date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment

Senti Biopharma shares rallied in premarket trading on Tuesday after its cancer treatment received a positive designation from the U.S. FDA.

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment 

Equity

Shares of Senti Biosciences Inc. skyrocketed over 400% on Monday afternoon, making it the top gainer across U.S. stock exchanges and the top trending ticker on Stocktwits.&nbsp;The surge was fueled by the biotech company’s announcement of an oversubscribed private placement and promising early clinical data for its experimental blood cancer treatment.&nbsp;The stock rallied to levels last seen in April 2023, drawing significant attention from retail investors.Senti disclosed that it had entered into a securities purchase agreement with existing and new accredited investors to raise approximately $37.6 million through the sale of Series A&nbsp;convertible preferred stock in a private investment in public equity (PIPE) financing.&nbsp;The deal includes warrants allowing investors to purchase up to an additional 25,069,500 shares of the company’s common stock, contingent on shareholder approval.&nbsp;Additionally, an option was granted to a specific investor to buy 4,444 more shares of preferred stock and accompanying warrants, potentially generating $10 million more in gross proceeds by Dec. 27.The PIPE financing, led by Celadon Partners and supported by institutional players like New Enterprise Associates, Leaps by Bayer, and Nantahala Capital, is expected to close by Thursday.&nbsp;Senti plans to use the proceeds to advance its SENTI-202 program, scale manufacturing capabilities, support ongoing R&amp;D efforts, and for general corporate purposes.Positive clinical data from the Phase 1 trial of SENTI-202 also contributed to the stock’s meteoric rise.&nbsp;The trial focused on treating acute myeloid leukemia and other relapsed or refractory hematologic cancers using Senti’s proprietary gene circuit technology.&nbsp;Initial results revealed that two of three treated patients achieved complete remission, confirmed by bone marrow biopsy, with both patients remaining in remission for three and four months, respectively.&nbsp;The treatment was reported to have a generally well-tolerated safety profile at the administered dose, with further trial updates expected next year as dose escalation continues.<figure class="image"><a href="https://stocktwits.com/symbol/SNTI"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SNTI_sentiment_meter_and_message_volume_on_Dec_2_42660f4d88.png" alt="SNTI sentiment meter and message volume on Dec 2.png" width="1314" height="320"></a><figcaption>SNTI sentiment meter and message volume on Dec 2 as of 1:00 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for SNTI turned ‘extremely bullish’ amid soaring message volume.<stembedurl>https://stocktwits.com/DJTAZ/message/594734529</stembedurl><stembedurl>https://stocktwits.com/Pianomemo/message/594734011</stembedurl>Year-to-date, Senti Biosciences shares have gained over 70%, with Monday’s explosive rally marking a pivotal moment for the company’s visibility in the biotech sector.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-rises-after-upgrade-price-target-hikes/cJ9kq43RhE">Tesla Stock Rises After Massive Price Target Hikes On Trump, AI Factors: Retail’s Charged Up</a>

Senti's deal includes warrants allowing investors to purchase up to an additional 25,069,500 shares of the company’s common stock

Senti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail Overjoyed

The stock rallied to levels last seen in April 2023, drawing significant attention from retail investors.

This account has been verified as an official SNTI representative.

Verified Account

Senti Biosciences

Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.

SNTI
Senti Biosciences Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest SNTI News

SNTISenti Biosciences Inc.